The Lyceum: AI Daily — May 13, 2026

Today's stories rhyme with each other: AI is leaving the demo stage and entering the procurement budget. Isomorphic Labs raised $2.1 billion to push AI-designed drugs toward actual human trials, China's State Council told its agencies to start buying AI agents rather than building them, and on the other end of the scale spectrum, a 26-million-parameter open-source router model is making a serious argument that the agent decision layer doesn't need a data center at all. The throughline is deployment economics — who pays, who installs, who patches it when it breaks.

• Granite 4.1 (IBM): An 8B-parameter model that IBM says performs comparably to 32B-parameter models on enterprise benchmarks — built for on-premises deployment where data can't leave the building.
• Needle (Cactus Compute): A 26M-parameter open-source function-call/router model distilled from Gemini 3.1 Flash Lite, running at 6,000 tokens/sec prefill on commodity hardware.
• Claude Sonnet 4.6 (Anthropic): Not a fresh drop — released February 17 — but worth flagging as the baseline most enterprises are now benchmarking new agent deployments against, with Anthropic explicitly pitching multi-step tool-use reliability over raw capability.

Isomorphic Labs, the Google DeepMind spinout trying to turn AlphaFold's protein-structure work into an actual drug pipeline, announced a $2.1 billion Series B led by Thrive Capital, with Alphabet, GV, MGX, Temasek, CapitalG, and the UK Sovereign AI Fund participating. That brings cumulative funding to roughly $2.6 billion — one of the largest private rounds ever in AI drug discovery, according to Ventureburn.

The capital goes toward scaling IsoDDE, Isomorphic's AI Drug Design Engine, and advancing programs through partnerships already signed with Novartis, Lilly, and Johnson & Johnson. But the more interesting line is buried in the Yahoo Finance coverage: the company now expects first clinical trials by the end of 2026 — a year's slip from Hassabis's earlier target of having AI-designed drugs dosing patients by end of 2025.

If this succeeds, an Isomorphic-designed molecule entering Phase I before year-end becomes the most consequential proof point in the short history of AI-for-biology, and the sovereign wealth funds writing checks here look prescient about treating drug design as strategic infrastructure rather than a venture bet. If it fails — meaning 2026 closes without an IND filing — the entire AI-bio valuation thesis faces its first hard stress test, and you'll see it first in the trial registries, not the press releases.

China's State Council issued new directives this week pushing for "deep implementation" of its "AI+" action plan and explicitly supporting government procurement of large models and "intelligent body" (agent) services, according to reporting compiled by Oriental Fortune and other Chinese-language outlets. The shift matters amid most AI policy stories that cover what governments want to restrict. This one is about what one government wants to buy.

Carnegie Endowment analysis from last year already documented Chinese state-owned enterprises and provincial governments accelerating AI adoption under political incentives. The new directive gives that trend top-level cover and a procurement mandate — turning Beijing into a guaranteed customer for its own AI industry, a demand-side subsidy Western labs simply can't replicate.

If this succeeds, expect Chinese labs — Baidu, Alibaba's Qwen team, and increasingly DeepSeek — to optimize aggressively for agent-capable, enterprise-deployable models over benchmark-leaderboard performance. The observable signal: watch which model providers start showing up in provincial procurement filings over the next quarter. [Source: Oriental Fortune and Sina Finance — Chinese (Simplified)]

A Washington Post analysis out this morning makes a deceptively simple argument: governments still can't agree on what "AI" actually is, and the definitional gap is becoming a real obstacle to coherent international governance. The EU's AI Act, U.S. executive orders, and China's regulations each use materially different definitions — some focused on autonomy, others on data-driven learning, others on generative capability.

The practical consequence is regulatory arbitrage at planetary scale. The same system might be "high-risk AI" in Brussels, "automated decision-making software" in Washington, and "intelligent software" in Beijing — and international agreements on safety, export controls, and liability are being negotiated by parties not actually talking about the same thing.

If this persists, the companies that win cross-border AI deployment aren't the ones with the best models — they're the ones with the best regulatory counsel. The signal to watch: whether the next G7 or OECD communiqué includes a unified technical definition, or whether it punts again.

A Korea Times opinion piece published today argues that recent model capability gains are already shifting the attacker/defender calculus in critical sectors — finance, energy, healthcare — and that existing defenses built for scripted attacks weren't designed to resist adaptive, model-driven probing. The author calls for "AI-resistant" software design patterns and layered defenses built with the assumption that exploit discovery itself is now scalable.

The piece is opinion, not breaking news, but it lands the same week Anthropic's Project Glasswing went public with large enterprises hunting zero-days at production scale. The two pieces of the same puzzle: defenders are getting AI tools faster, but so are attackers, and the first high-profile breach traced directly to AI-assisted exploit discovery will likely reshape procurement language overnight.

The signal to watch: when "AI-resistant design" starts appearing as a line item in enterprise RFPs, not just opinion columns. [Source: The Korea Times — English (Korean publication)]

Cactus Compute distilled Gemini 3.1 Flash Lite into a 26-million-parameter "Simple Attention Network" — essentially a transformer with the feedforward layers stripped out — and posted it to GitHub with open weights. In benchmarks Cactus published in its own architecture notes, Needle runs at 6,000 tokens/sec prefill and 1,200 tokens/sec decode on commodity hardware. The training cost is the other tell: 200 billion pretraining tokens on 16 TPU v6e chips over 27 hours, then 45 minutes of post-training on 2 billion synthetic function-calling tokens, according to Startup Fortune's writeup.

The architectural claim — that the MLP layers carrying most of a transformer's parameters can be dropped entirely if the model relies on external knowledge (like a tools list) — is the kind of thing that tends to get replicated quickly if it holds. The project pulled roughly 400 points on Hacker News.

If this approach generalizes, the agent router layer moves to the edge, latency drops, and API bills for tool-selection traffic collapse. If it doesn't replicate, it's still an interesting Show HN. Treat it as a research signal, not a shipping product — but the engagement velocity suggests practitioners are taking the architectural argument seriously.

A community signal worth flagging carefully: a thread on r/singularity claims OpenAI's GPT-5.5 at high reasoning effort became the first model to solve a task on ProgramBench — a benchmark where the model receives only a compiled binary and usage documentation, then must reconstruct the program from scratch (no source, no decompilation, no internet). BenchLM's documentation confirms the benchmark's existence and methodology; the GPT-5.5 result itself is community-reported and not yet independently replicated.

The credibility caveat matters. A parallel Hacker News thread is already arguing that ProgramBench may be measuring memorization of well-known open-source programs more than novel engineering ability — exactly the kind of methodological fight that surfaces when a leaderboard result moves faster than the eval's assumptions get audited.

If the result holds up under independent testing, it reshapes enterprise procurement narratives for the next cycle — "first model to solve X" is exactly the framing that moves CIO conversations. If it doesn't, it's another reminder that the benchmark wars are as much about narrative as numbers.

A quiet policy signal: FTC Commissioner Andrew Ferguson, joined by Commissioner Melissa Holyoak, published a statement blessing publication of the staff report from the Commission's 6(b) study of Microsoft–OpenAI, Amazon–Anthropic, and Google–Anthropic partnerships — while warning readers to treat the report's broader speculation "with tremendous skepticism." The underlying study isn't new. The interpretive frame is.

That's a tone shift from the prior Commission's posture that these cloud-AI tie-ups looked structurally dangerous, toward something closer to "watch them, but don't overread them." It's not a reopened case or new enforcement — it's the regulator now holding the pen telling the field how to read the file.

If this frame holds, the deals defining frontier AI's supply chain get more breathing room. The signal to watch: whether DOJ Antitrust adopts a similar posture, or whether the two agencies diverge.

Today the world's most expensive guessing game got a $2.1 billion player who's running a year behind schedule, Beijing turned itself into AI's largest captive customer, and a 26-million-parameter model casually argued that most of a transformer is decorative. Somewhere in a regulator's office, two commissioners are pleading with you to treat their own staff report with tremendous skepticism — which is itself the most candid thing anyone in Washington has said about AI partnerships in a year. Tomorrow is Google I/O; pour the coffee accordingly.

Forward this to the friend who keeps asking what's actually changing in AI — this is the answer.